Jenburkt Pharmaceuticals Ltd
Ticker: JENBURPH
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
1272.90
Market Cap
561.77
Debt/Equity
0.0227
ROE %
20.252
PB
3.2705
Promoter %
46.658
Pledge %
0.000
1Y Rev Growth %
8.026
5Y Rev Growth %
5.171
NP Margin %
20.245
NP Margin 5Y Avg %
17.425
Trading Reference
1M Return %
4.281
6M Return %
23.817
1Y Return %
32.539
% Away 52W High
10.771
% Away 52W Low
35.892
Daily Volume
29431
Investment Verdict
Hold
Score 66/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Watch
Score 61/100 · Position size: 10%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
More Options
T
Thomas Scott (India) Ltd
The stock has potential but faces challenges in growth consistency and profitability metrics.
View details
U
UMA Converter Ltd
UMA Converter Ltd shows several weaknesses across key metrics, indicating a risky investment proposition.
View details
N
Nikhil Adhesives Ltd
Nikhil Adhesives Ltd shows potential in a growing sector but faces challenges in profitability and market sentiment.
View details
C
Cybertech Systems and Software Ltd
Cybertech Systems and Software Ltd presents a risky investment due to inconsistent growth and profitability metrics, alongside weak market sentiment.
View details
N
Nahar Capital and Financial Services Ltd
The stock presents several risks with limited growth prospects and weak market sentiment, making it a risky investment.
View details
K
Kriti Nutrients Ltd
Kriti Nutrients Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
A
Andhra Petrochemicals Ltd
Andhra Petrochemicals Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Aditya BSL Nifty 50 ETF
The Aditya BSL Nifty 50 ETF presents a decent investment opportunity with a stable outlook, driven by the performance of its underlying assets.
View details
L
Lehar Footwears Ltd
Lehar Footwears Ltd shows potential but faces significant risks and inconsistencies in growth and profitability.
View details
I
India Finsec Ltd
India Finsec Ltd shows potential but faces significant risks and challenges in growth and profitability.
View details
S
Stovec Industries Ltd
Stovec Industries Ltd shows potential but faces challenges in growth consistency and valuation. Investors should proceed with caution.
View details
I
India Homes Ltd
India Homes Ltd shows potential but faces significant challenges in profitability and valuation metrics, making it a cautious investment.
View details
W
W S Industries (India) Ltd
W S Industries shows potential in a growing sector, but faces challenges in consistent growth and profitability. Caution is advised due to execution risks and market sentiment.
View details
R
Raghuvir Synthetics Ltd
Raghuvir Synthetics Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
J
JAYBEE Laminations Ltd
JAYBEE Laminations Ltd faces several challenges, including inconsistent growth and market sentiment. Caution is advised for potential investors.
View details
B
Bhatia Colour Chem Ltd
Bhatia Colour Chem Ltd presents a risky investment opportunity due to inconsistent growth and weak market sentiment.
View details
Business Overview
Jenburkt Pharmaceuticals Ltd is a prominent player in the Indian pharmaceutical industry, dedicated to delivering high-quality healthcare solutions. Catering to diverse therapeutic segments, the company focuses on innovation and accessibility, ensuring that essential medicines reach those in need. With a commitment to excellence and patient care, Jenburkt plays a vital role in enhancing health outcomes across the nation. Its strong R&D capabilities and robust distribution network further solidify its position in the market.
- Established leader in the Indian pharma sector
- Focus on diverse therapeutic areas
- Commitment to quality and innovation
- Strong R&D capabilities
- Extensive distribution network
- Enhancing health outcomes for millions
Investment Thesis
Jenburkt Pharmaceuticals Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. These factors position the company for robust future performance in the pharmaceutical sector.
- Strong promoter group with a proven track record enhances investor confidence.
- Expansion into digital services offers a substantial growth runway.
- Valuation metrics indicate attractive pricing relative to industry peers.
- Focus on innovation and quality positions the company for long-term success.
- Solid financial performance and growth prospects make it a worthy addition to any portfolio.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Expansion into new markets
- Strong R&D pipeline
- Strategic partnerships with hospitals
- Increase in online sales channels
Risks ⚠️
- Regulatory challenges in pharmaceuticals
- Intense competition in the sector
- Fluctuating raw material costs
- Dependence on key customers
- Potential supply chain disruptions
Peer Perspective
Jenburkt Pharmaceuticals Ltd trades at a discount to peers like Sun Pharmaceutical and Lupin, primarily due to margin volatility. A stable margin improvement could trigger a rerating, aligning its valuation more closely with industry leaders.
Future Outlook
Jenburkt Pharmaceuticals Ltd is well-positioned for growth, driven by strong product pipelines and market expansion. Continued focus on execution and cost control will be crucial to maximizing shareholder value in the coming years.
📊 Stock Investment Checklist (100 Points)
Jenburkt Pharmaceuticals Ltd • Updated: 2025-09-18 00:30:45
-
10BusinessHighPharmaceutical sector is essential and growing, but competition is high.
-
10GrowthHighConsistent revenue growth over the past few years, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but cash flow is inconsistent.
-
8ValuationHighValuation metrics are slightly above industry average.
-
7BalanceHighModerate debt levels, but liquidity is adequate.
-
6GovernanceGoodPromoter holding is strong, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are notable.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Jenburkt Pharmaceuticals Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100